Dr Reddy’s Lab – Sales Growth Without Margin Improvement
Dr Reddy’s Q1 FY12 result was in line with our sales estimate however, was below our EBITDA and net income estimates. Sales growth was driven largely by its US generics business – compensating for the muted performance in domestic formulations, Bulk exports and German business. However, despite gains in market share of low competition products like lanzoprazole, tacrolimus, omeprazole OTC and fexofenadine OTC. In addition to this, with lower contribution from API, the sales mix too was in favor of a better margin . We still like DRRD’s low competition products pipeline with generic Zyprexa and generic Fosamax D being the biggest opportunities in FY12, however, that the valuations are nearly full and exposing the investor to the risks of execution. We reiterate our Market Perform rating on Dr Reddy’s.
COMPANIES MENTIONED
Dr Reddy’s
Dr Reddy’s
More Publications
Dr Reddy's lab - US Drives Sales Growth, API saves margin.
US$ 140.00
October 2011
8 pages
DR REDDY’S LAB - Olanzapine and Forex Drive Growth
US$ 140.00
February 2012
5 pages
IPCA - Sales Growth + Margin Improvement + Stock Price Correction = Ideal Time To Enter
US$ 140.00
October 2011
7 pages
BIOGEN IDEC - Data of BG-12 + Sales Growth Brighten 2012 Prospects
US$ 140.00
November 2011
6 pages
IPCA- Margin Improvement, Despite Lower Domestic Sales
US$ 140.00
August 2011
5 pages
